Fosun Medicine: it is difficult to predict the sales of COVID-19-related products in the future

Fosun Pharmaceutical: future sales of COVID-19-related products are difficult to predict. At the 2022 annual performance meeting held today, Wu Yifang, executive director and chairman of Fosun Pharmaceuticals, told the Financial Associated Press that a total of 15.55 million doses of Fubitai COVID-19 vaccine and 6.74 million bottles of Azvudine were sold in 2022. The sales of COVID-19-related products are strongly related to infection, and it is difficult to predict future sales. This year, the company will continue to focus on other innovative products to fill the increment. (financial Associated Press reporter Lu Afeng)